Cleveland BioLabs, Inc. made a statement today announcing its board of directors has appointed Randy S. Saluck, J.D., a shareholder representative, as an independent director.
Chief Executive Officer Yakov Kogan commented, “Randy has been a shareholder of CBLI since 2009 and brings more than 20 years of experience on Wall Street to our Board. We believe Randy’s knowledge of the company and background, as a senior analyst or portfolio manager at several hedge funds with assets under management ranging from $50 million to over $3 billion, will provide us with critical shareholder perspective on our strategic decisions and help us safeguard shareholder value.”
Salucks experience includes being a Managing Member of Mortar Rock Capital Management, LLC as well as the Portfolio Manager of Mortar Rock Capital LP since 2005. Prior to Mortar Rock Capital, Saluck was a portfolio manager at the investment fund of Meisenbach Capital, LP. A well-versed executive, Saluck’s resume also includes investment management experience, overseeing special situations, and risk arbitrage.
Saluck is a corporate and securities attorney turned investment banker. He previously worked at Cahill Gordon & Reindel LLP and then Tenzer Greenblatt LLP. As an attorney, Mr. Saluck worked with a variety of small capitalization companies. He assisted them in the implementation of strategic plans and financing. Saluck holds an MBA from the Wharton School of the University of Pennsylvania with a concentration in finance and accounting. Saluck currently sits on the Board of Directors of the Connecticut Region of the Anti-Defamation League.
In addition, Cleveland BioLabs announced today that it will hold its 2013 annual stockholders meeting at 10:00 a.m. eastern time on June 14, 2013, at the Company’s headquarters located at 73 High Street, Buffalo, NY, 14203. This will be held for stockholders of record as of April 16, 2013. The Company will distribute proxy materials to all eligible stockholders.
Live webcasts of stockholders meetings will be available on the investor page of Cleveland BioLab’s Web site located at www.cbiolabs.com
Let us hear your thoughts below:
